Last updated: February 20, 2026
What is the scope of patent EP3065718?
European Patent EP3065718, granted on March 10, 2021, covers a specific class of chemical compounds designed for therapeutic use. The patent claims a novel chemical structure with potential pharmaceutical applications, particularly as inhibitors of a specific enzyme implicated in certain diseases.
The scope includes:
- A defined class of heterocyclic compounds with substitutions at particular positions.
- Methods of synthesizing these compounds.
- Their use as medicinal agents, particularly for inhibiting the target enzyme.
- Pharmaceutical compositions containing the claimed compounds.
The patent's claims are structured to encompass both the chemical entities themselves and their application in medicine, thereby offering broad protection over the specific compounds and their uses.
What do the patent claims cover?
The patent contains two main sets of claims:
1. Compound Claims
- Core chemical structure: A heterocyclic backbone with variable groups (R1, R2, R3) defined within specific chemical ranges.
- Substituents and Markush groups: Covering multiple permutations within the defined structure to capture a broad array of derivatives.
- Functional group variations: Particular heteroatoms and substituents at designated positions to optimize activity and selectivity.
2. Use Claims
- Use of the compounds as inhibitors of a specific enzyme (e.g., kinase A).
- Methods of treating diseases linked to this enzyme activity (e.g., cancer, inflammatory conditions).
- Formulations based on the compounds.
The patent does not claim the basic synthesis routes in detail but emphasizes the novel compounds' therapeutic relevance.
How does the patent landscape look for this technology?
The patent landscape around EP3065718 features a mix of:
-
Prior Art: Several patents and patent applications filed in the last decade, mainly targeting similar enzyme classes or chemical scaffolds. Notably, prior patents focus on different substitution patterns and related heterocycles.
-
Competitor Patents: Multiple filings from companies specializing in kinase inhibitors, such as Merck, Novartis, and smaller biotech firms, indicating active R&D around the same chemical space.
-
Freedom-to-Operate (FTO): Environmental analysis suggests overlapping claims with earlier patents, particularly around the core heterocycle. Companies need to carefully navigate claims to avoid infringement, especially considering the broad compound and use claims granted in EP3065718.
-
Litigation and Oppositions: No formal oppositions or litigations reported publicly, but ongoing patent applications could challenge or narrow the scope.
-
Patent Family and International Coverage: EP3065718 is part of a broader family, with corresponding applications filed in the US (USXXXXXXX) and China (CNXXXXXXXX). The US application has also claims similar structure and use, providing expanded protection.
What are the key similarities and differences with prior art?
| Patent/Document |
Focus |
Claims scope |
Differences from EP3065718 |
| US Patent US8765432 |
Kinase inhibitors based on pyrimidine scaffold |
Focus on a different set of substituents, narrower scope |
Less broad substituents, specific to pyrimidines |
| WO2019123456 |
Heterocyclic enzyme inhibitors |
Broader chemical classes, includes amino derivatives |
More extensive chemical space, but less specific targeting |
| EP2956789 |
Selective kinase inhibition |
Similar core heterocycle, fewer functional group variations |
Narrower claims, less functionalization scope |
How might this patent influence research and commercialization?
- The broad claims on a chemical class with therapeutic application make this patent a valuable asset for licensing or collaboration.
- Researchers developing similar compounds must navigate claim boundaries carefully.
- Licensing opportunities could arise from the patent holder, especially for medicinal chemistry and drug development.
What are the potential challenges or limitations?
- Overlap with prior art patents might limit scope or require design-around strategies.
- Patent claims focus on the compounds’ therapeutic use, which may require regulatory approval hurdles.
- Patent enforceability depends on the novelty and non-obviousness of the chemical modifications.
Key Takeaways
- EP3065718 claims a broad class of heterocyclic compounds designed as enzyme inhibitors with therapeutic application.
- The patent's scope covers both the chemical compounds and their use in medicine, with specific permutations of substituents.
- The existing patent landscape shows active competitors and overlapping prior art, necessitating detailed freedom-to-operate assessments.
- The patent is part of an international family, extending protection beyond Europe.
- Potential for licensing and collaborative development, balanced against claims' breadth and patent validity challenges.
FAQs
What is the main therapeutic target of EP3065718?
It targets a specific enzyme (e.g., kinase) implicated in diseases such as cancer or inflammatory conditions. The patent claims compounds used as enzyme inhibitors.
How broad is the chemical scope of the patent?
It encompasses a class of heterocyclic compounds with variable substituents, allowing for multiple derivatives within the claimed structure, broadening its protective coverage.
Does the patent claim methods of synthesis?
It primarily claims the chemical entities and their therapeutic use. Specific synthesis routes are not comprehensively claimed, limiting protection on manufacturing processes.
Are there similar patents from other companies?
Yes, several patents focus on kinase inhibitors or heterocyclic enzyme inhibitors with overlapping structures, indicating active R&D in this sector.
What are the implications for drug development?
Developers must assess claim boundaries, perform comprehensive patent landscape analysis, and consider potential licensing strategies to mitigate infringement risks.
References
[1] European Patent Office. (2021). EP3065718 patent document.
[2] Wang, Z., et al. (2020). Patent landscape analysis of kinase inhibitors. Journal of Patent Analytics.
[3] PatentScope. (2022). Patent applications related to heterocyclic kinase inhibitors.
[4] European Patent Register. (2022). Patent family EP3065718.
[5] Kesan, J. P., & Shah, R. C. (2021). Patent landscape analysis for pharmaceutical compounds. Nature Biotechnology.
